Market Overview

UPDATE: Morgan Stanley Raises PT on Baxter International on Neutral Risk-Reward

Related BAX
Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives & Negatives
Halozyme Therapeutics Receives Favorable FDA Decision
Merck Snags Baxter Executive As CFO (Fox Business)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Baxter International (NYSE: BAX), and raised the price target from $71.00 to $84.00.

In the report, Lewis noted, “We see a neutral risk-reward into Baxter's highly-anticipated PIII Alzheimer's data. We estimate the stock price currently includes roughly $3-5 in AD optionality, placing likely downside at 3-10% for a total failure (missed primary endpoints, missed subgroup analyses). Upside in the unlikely (p=5%) case of success on both primary endpoints could be $6-11, or 8-15%. Several intermediate cases of mixed results or suggestive subgroup analyses could drive less extreme outcomes and will likely punt investment implications until the presentation of full data results.”

Baxter International closed on Friday at $70.94.

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters